Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000
Backer Marianne De Sells 72,559 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
Vir Biotechnology, Inc. $VIR Shares Sold by Citigroup Inc.
Vir Biotechnology to Participate in Upcoming Investor Conferences
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Vir Biotechnology Announces Proposed Public Offering of Common Stock
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
These Analysts Boost Their Forecasts On Vir Biotechnology
Stock Market Today: S&P 500 Futures Slip As Dow, Nasdaq 100 Gain Following Trump's Tariff Threat — Whirlpool, Uber, HP In Focus (UPDATED)
What's Happening With VIR Stock?
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates
Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $17.00 Consensus Price Target from Brokerages
Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares of Stock
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of “Moderate Buy” by Brokerages
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $17.30 Consensus Price Target from Brokerages
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025